Edgewise Therapeutics (EWTX) P/B ratio

P/B ratio today
8.3×

Edgewise Therapeutics (EWTX) trades at 8.3× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 4.9×. That is 11.2% lower than the 5.5× of fiscal 2024. Figures as of 18 Nov 2026, 09:33 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
8.3×
P/B ratio, fiscal 2025
4.9×
Change on fiscal 2024
−11.2%
Highest on record
5.5×fiscal 2024
Lowest on record
1.6×fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Edgewise Therapeutics P/B ratio, in more detail

Today's figure is 69.4% above the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 5.5× in fiscal 2024 and the lowest 1.6× in fiscal 2022. Today's P/B ratio is above every one of the 4 fiscal year-ends on record; their median is 3.5×.

History · 4 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Edgewise Therapeutics P/B ratio, year by year

Edgewise Therapeutics (EWTX) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today8.3×—$42.04—
20254.9× 11.2% down$24.82$5.07
20245.5× 151.9% up$26.70$4.85
20232.2× 34.1% up$10.94$5.00
20221.6×—$8.94$5.48
2021——$15.28—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

P/B ratio at health care companies of similar size

P/B ratio of Edgewise Therapeutics and comparable companies
CompanyP/B ratio
Concentra Group Holdings Parent CON13.5×
Merit Medical Systems MMSI3.2×
Edgewise Therapeutics EWTX8.8×
LivaNova LIVN4.2×
Ionis Pharmaceuticals IONS9.2×
Dianthus Therapeutics DNTH9.9×

Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.

More on EWTX

Edgewise Therapeutics, figure by figure

Edgewise Therapeutics (EWTX) overview: price, valuation and scorecardAll health care companies by market value

Edgewise Therapeutics P/B ratio: questions and answers

What is Edgewise Therapeutics's P/B ratio?

Edgewise Therapeutics (EWTX) trades at 8.3× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 4.9×. That is 11.2% lower than the 5.5× of fiscal 2024.

Is Edgewise Therapeutics's P/B ratio high or low compared with its own history?

Today's P/B ratio is above every one of the 4 fiscal year-ends on record; their median is 3.5×.

What are the highest and lowest P/B ratio figures on record for Edgewise Therapeutics?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 5.5× in fiscal 2024 and the lowest 1.6× in fiscal 2022.

How is Edgewise Therapeutics's P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Edgewise Therapeutics it is on record here for 4 fiscal years, 2022 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Edgewise Therapeutics (EWTX) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/EWTX/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.